ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Immunogen, Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Immunogen, Inc. market cap is $8.72B.
What is the 52-week high for Immunogen, Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Immunogen, Inc. 52 week high is $31.25 as of September 11, 2025.
What is the 52-week low for Immunogen, Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Immunogen, Inc. 52 week low is $3.61 as of September 11, 2025.
What is Immunogen, Inc. stock price today?
Immunogen, Inc. stock price today is $31.23.
What was Immunogen, Inc. stock price yesterday?
Immunogen, Inc. stock price yesterday was $31.23.
What is the PE ratio of Immunogen, Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Immunogen, Inc.’s P/E ratio is -104.24.
What is the Price-to-Book ratio of Immunogen, Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Immunogen, Inc. P/B ratio is 14.7833.
What is Immunogen, Inc.'s EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Immunogen, Inc.'s EBITDA is -51.86.
What is the 50-day moving average of Immunogen, Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Immunogen, Inc. 50-day moving average is $29.88.
